戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  a promising candidate for exploration as an anti-HIV agent.
2 icacy of PNA(TAR)-transportan as a potential anti-HIV agent.
3 tating identification of the next generation anti-HIV agents.
4  interactions warrant the development of new anti-HIV agents.
5 cilitate the development of a novel class of anti-HIV agents.
6  from the library failed to yield any active anti-HIV agents.
7 will lead to the discovery of a new class of anti-HIV agents.
8 tic basis for the discovery of new selective anti-HIV agents.
9  L-2'F-C-d4Ns) were synthesized as potential anti-HIV agents.
10 ies, which may aid in the development of new anti-HIV agents.
11 novel and selective antiviral, in particular anti-HIV agents.
12 described identify new potential targets for anti-HIV agents.
13  resistant to all of the currently available anti-HIV agents.
14 heir consideration as therapeutically useful anti-HIV agents.
15 he development of biopharmaceutically useful anti-HIV agents.
16 the pharmacokinetics and pharmacodynamics of anti-HIV agents.
17 novel N-DABOs were synthesized and tested as anti-HIV agents.
18 studies of the novel diheteroarylamide-based anti-HIV agent 2 (1C8), one objective was to evaluate th
19       The anti-human immunodeficiency virus (anti-HIV) agent 2',3'-didehydro-3'-deoxythymidine (D4T),
20  of (+)-cis-khellactone derivatives as novel anti-HIV agents, 24 monosubstituted 3', 4'-di-O-(S)-camp
21 rugs in the brain is expected to produce the anti-HIV agent, 9-(2,3-dideoxy-2-fluoro-beta-D-threo-pen
22  amidates 2a, 2b, 4a, 4b, and 6 derived from anti-HIV agent adenallene 1a, 3a, inactive hypoxallene 1
23                                Both a potent anti-HIV agent and an efficient formulation are required
24 ty relationships (SAR) of triterpene-derived anti-HIV agents and led to the design and synthesis of c
25 carboxypeptidase lability translated to poor anti-HIV agents and vice versa, so the assay became pred
26                                        Novel anti-HIV agents are still needed to overcome resistance
27 -tetraazamacrocycle xylyl-bicyclam, a potent anti-HIV agent, by the coreceptor CXCR4, a G-protein-cou
28                                          The anti-HIV agent (+/-)-calanolide A (1) has been synthesiz
29 at Gd-Tex may have therapeutic utility as an anti-HIV agent capable of selectively targeting and remo
30                                          The anti-HIV agent cosalane inhibits both the binding of gp1
31 ine the role of the cholestane moiety in the anti-HIV agent cosalane, a series of cosalane analogs wa
32 on of our previous works in the discovery of anti-HIV agents, D- and L-2',3'-unsaturated 3'-fluoro ca
33 ng study of triterpene derivatives as potent anti-HIV agents, different C-3 conformationally restrict
34 on towards enantioselective synthesis of the anti-HIV agent (-)-equisetin.
35 ith cancer, TPT is unlikely to be used as an anti-HIV agent in clinic, but our study provides proof t
36 f great interest which is not reached by any anti-HIV agent in clinical use.
37 nscriptase inhibitors (NNRTIs) are effective anti-HIV agents in cell culture.
38 ology to the total synthesis of siamenol, an anti-HIV agent, is reported.
39 synthesis of antiobesity drug Rimonabant and anti-HIV agent PNU-32945.
40  was found to possess enhanced potency as an anti-HIV agent relative to cosalane itself.
41 ding more than a gram of a major fragment of anti-HIV agents rubriflordilactones A and B and a specif
42 ucture-activity relationship study of potent anti-HIV agents, seven new triterpene derivatives were d
43              In a continuing study of potent anti-HIV agents, seventeen 28,30-disubstituted betulinic
44 de designed as a conformational mimic of the anti-HIV agent stavudine (1, D4T) is described.
45 nal ring (IVR) for sustained delivery of the anti-HIV agent tenofovir (TFV) are described.
46                     Bevirimat (1, BVM) is an anti-HIV agent that blocks HIV-1 replication by interfer
47  are safe, and thus, if developed for use as anti-HIV agents, they could reduce both HIV replication
48 nd 29, which were confirmed as highly potent anti-HIV agents with activities in the 10-20 nM range.
49 llene 1a and (R)-enantiomer 3a are effective anti-HIV agents with EC50 approximately 0.88 and 0.21 mi
50 ying of several polychloro-analogs did yield anti-HIV agents with EC50 values as low as 310 nM.